Bioventus Inc - Ordinary Shares - Class A
BVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$576.54M
Close$
$25.41
197.1% upside
Current Fair Value
197.1% upsideUndervalued by 197.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $576.54 Million |
|---|---|
| Enterprise Value | $559.44 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.34 |
| Beta | 0.72 |
| Outstanding Shares | 67,296,336 |
Return
| Return on Equity | 15.08% |
|---|---|
| Return on Assets | 4.38% |
| Return on Invested Capital | 12.61% |
Valuation & Multiples
| P/E Ratio | 20.11 |
|---|---|
| PEG | -9.22 |
| Price to Sales | 1.07 |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | 0.97 |
| Enterprise Value to EBIT | 8.83 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$130.32 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$155.45 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2377▲ 23.77% |
|---|---|
| Total Calls | 164,500▲ 62.39% |
| Total Puts | 39,100▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.64%▲ 1.65% |
|---|---|
| Total Invested | $466.38M▲ 24.93% |
| Investors Holding | 159▲ 10.00% |
ESG Score
No data
About Bioventus Inc
700 employeesBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioven...